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We agree with Drs Chu and Peters that non-invasive prenatal testing (NIPT) is not perfectly reliable. Indeed, a positive cell-free DNA testing result does not always imply the presence of fetal aneuploidy. As it was specified by Drs Chu and Peters in their Letters to the Editor, Wang et al., reported that NIPT can have very high false-positive rates, for instance up to 7% for trisomy 21 detection (Wang et al., 2014) . This finding illustrates the necessity to be careful in the case of positive results and to confirm them systematically before taking any decision concerning the pregnancy management. Moreover, it is also important to understand the possible causes of discordant results that decrease the positive predictive value of this test, in order to improve its clinical development and applications.
In our review we aimed mainly to highlight the emerging role of circulating nucleic acids as non-invasive tools for the detection of ovarian disorders and for the prediction of in vitro fertilization (IVF) outcome. Indeed, currently we quantify cell-free DNA (cfDNA) concentration and microRNA expression in biological fluids in order to develop new non-invasive diagnostic and/or prognostic tests in human reproductive medicine that could be used to improve IVF outcome. For instance, we have already shown that the analysis of cell-free DNA in follicular fluid samples might offer the possibility to develop a non-invasive test for the selection of the embryos with the highest implantation potential (Scalici et al., 2014 Diagnostic and management modalities in early tubal ectopic pregnancy with focus on safety Sir, The paper by Kirk et al. (2014) on diagnostic modalities for ectopic pregnancy (EP) and management of pregnancy of unknown location (PUL) is a very succinct and balanced review covering a wide range of important issues. The discussion about the role of ultrasound scanning combined with serial human chorionic gonadotrophin (bhCG) estimation in diagnosis of tubal EP is particularly useful. This letter further debates a few particular aspects. Kirk et al. (2014) state that in their specialist early pregnancy unit (EPU) up to 73.9% of EP were visualized on transvaginal ultrasound scan (TVUS). The most common finding (60%) was a 'nonhomogeneous mass' in the adnexa separate from the ovary (a blob sign). However, other pathologies (e.g. broad ligament fibroids, ovarian cysts, fimbrial cysts or even faecoliths) can be mistaken for a blob sign as indeed pointed out by Kirk et al. (2014) . For these reasons the 'American consensus statement on nomenclature of PUL' reserves the term 'definite EP' to those when an extra-uterine gestation sac containing a yolk sac or fetal pole is visualized (Barnhart et al., 2011) and 'blob sign' is called 'probable ectopic' pregnancy. Kirk et al. (2014) have pointed out how this distinction is crucial when treatment with methotrexate is considered. Hence it could be argued that it would be preferable to have one standard safe terminology (i.e. 'probable ectopic' for a blob sign), otherwise a potential risk of someone somewhere inadvertently administering methotrexate to an early viable intrauterine pregnancy is instigated.
Secondly, many EPUs in the UK do not perform TVUS before 6 weeks (when dates known) unless there is pain in addition to bleeding. This reasonable strategy seems useful in reducing the incidence of PULs. Moreover, the experience of many EPUs in district general hospitals is that a significant proportion of early unruptured ectopic pregnancies may not be visualized on TVUS and scans are generally not repeated before 7-10 days unless there is increased acute pain. Hence, many units depend on combination of TVUS and serial bhCG estimation to diagnose tubal ectopic pregnancy. Kirk et al. (2014) have very well highlighted the false positive and negative rates of such an approach. Every protocol/ guideline on methotrexate treatment for EP should mention at the outset that a possibility of intrauterine pregnancy must be ruled out. A suboptimal rise of bhCG of ,35% over 48 h may be one option (Kirk et al., 2014) . The other option could be to require suboptimal rise of ,53% on at least two occasions 48 h apart and absence of intrauterine pregnancy on TVUS before methotrexate is administered (Sholapurkar, 2015) . National Institute for Health and Care Excellence (NICE) recommends methotrexate as preferred option below bhCG of 1500 IU/l but on the presumption that intrauterine pregnancy has been ruled out although this needs to be emphasized as mentioned above. Most ectopic pregnancies with low (less than 1500-2000 IU/l) and falling bhCG titres could be managed expectantly. On the other hand, methotrexate treatment has quite good success rate in other minimally symptomatic cases or indeed when expectant management fails (Sholapurkar, 2015) .
